Publications by authors named "T Ilus"
Purpose: To analyze treatment persistence and treatment outcomes of vedolizumab as first-line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a Finnish real-world setting.
Methods: Observational, retrospective, multi-center chart review study that included adult CD and UC patients initiating vedolizumab as first-line biological treatment between 2014 and 2020.
Results: The cohort consisted of 54 CD and 69 UC patients.
Impact of Cigarette Smoking on Clinical Presentation and Treatment Response in Coeliac Disease.
J Gastrointestin Liver Dis
June 2024
Background And Aims: The environmental factors, apart from gluten ingestion predisposing to coeliac disease are poorly known. Smoking is associated with many immune-mediated diseases, but research on coeliac disease is scarce. This study aims to investigate how smoking affects the clinical presentation, presence of comorbidities and response to gluten-free diet in coeliac disease.
View Article and Find Full Text PDFObjectives: It has been suggested that celiac disease could be diagnosed non-invasively in adults with transglutaminase antibody (TGA) levels >10x upper limit of normal (ULN). It is, however, unclear if high values signify more advanced disease and higher risk of co-morbidities. We investigated the association between the TGA levels, clinical characteristics and non-celiac endoscopic findings.
View Article and Find Full Text PDFBackground And Aims: The early outcomes of ulcerative colitis (UC) after rescue therapy with cyclosporine A (CyA) are well known. Published data on the safety of this treatment in perioperative use and data on the long-term prognosis are scarce and are investigated here.
Methods: All UC patients treated with CyA in Tampere University Hospital between 2009 and 2018 were reviewed from patient records.
Article Synopsis
- Researchers investigated dual biological therapy (DBT) as a new treatment for patients with refractory inflammatory bowel disease (IBD), focusing on its efficacy and safety.
- The study included 16 patients, mainly with Crohn's disease, who underwent 22 trials of DBT using combinations like adalimumab and ustekinumab, with a median follow-up of nine months.
- Results showed that 32% of patients achieved remission, some experienced reduced corticosteroid reliance, and notable safety concerns included a 19% infection rate, indicating the need for further long-term studies on DBT.